MDGL vs PCVX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MDGL · Madrigal Pharmaceuticals$399.63 ▼ 0.12%
PCVX · Vaxcyte$63.89 ▲ 3.18%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MDGL -19.4%
- PCVX +48.9%
Head to head
| Metric | MDGL | PCVX |
|---|---|---|
| Price | $399.63 | $63.89 |
| Change today | ▼ 0.12% | ▲ 3.18% |
| Market cap | $9.28B | $10.11B |
| Return, 3 months | -22.5% | +9.6% |
| Return, year to date | -31.4% | +38.5% |
| Return, 1 year | -18.3% | +53.4% |
| P/E (TTM) | -49.6 | -7.9 |
| P/B | 14.8 | 4.1 |
| P/E percentile vs own 5y | 24th | 88th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +71.2% | – |
| Net profit growth (YoY) | -37.0% | -70.7% |
| Gross margin | 91.5% | – |
| Operating margin | -25.1% | – |
| Net margin | -25.3% | – |
| Return on equity | -53.3% | -36.5% |
| Analyst target vs. price | +71.9% | +92.1% |
| Analyst buy share | 89% | 88% |
| RSI (14) | 24 | 53 |
| 30-day volatility | 34.2% | 100.2% |
| Max drawdown, 1 year | -34.3% | -28.0% |
| Trend read | Strong downtrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PCVX is the largest of the group by market value.
- PCVX has returned the most over the past year.
- MDGL carries the lowest trailing P/E.
- MDGL has been the calmest stock over the last 30 days.